EGRX 股息： Eagle Pharmaceuticals Inc 收益洞察

Q: Eagle Pharmaceuticals Inc 的关键财务报表是什么？

根据最新的财务报表（Form-10K），Eagle Pharmaceuticals Inc 的总资产为 $406，净利润为 $35

Q: EGRX 的关键财务比率是什么？

Eagle Pharmaceuticals Inc 的流动比率是 2.36，净利 margin 为 11.07，每股销售为 $24.12。

Q: Eagle Pharmaceuticals Inc 的收入按细分市场或地理位置如何划分？

Eagle Pharmaceuticals Inc 最大收入来源是 Metal Cutting，在最近的收益报告中收入为 1,280,781,000。就地区而言， United States 是 Eagle Pharmaceuticals Inc 的主要市场，收入为 824,275,000。

Q: Eagle Pharmaceuticals Inc 是否盈利？

是的，根据最新的财务报表，Eagle Pharmaceuticals Inc 的净利润为 $35

Q: Eagle Pharmaceuticals Inc 有负债吗？

是的，Eagle Pharmaceuticals Inc 的负债为 172

Q: Eagle Pharmaceuticals Inc 的流通股有多少？

Eagle Pharmaceuticals Inc 的总流通股为 13

主页

股票

EGRX

EGRX 财务

Eagle Pharmaceuticals Inc

$0.5

-41.17%

$-0.35

收盘价：Jan 16, 16:00:00 GMT-5

$0.5

盘前：Jan 20, 07:07:18 GMT-5

概述预测收益股息财务数据

收入

资产负债表

现金流量

年度

季度性

EGRX 收入

以百万美元为单位的财务数据。财年为2月至次年1月。

Breakdown	TTM	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
营收	257	316	171	187	195	213
营收同比增长 (YoY)	-6%	85%	-9%	-4%	-8%	-10%
营收成本	77	94	42	45	60	61
毛利润	179	221	129	142	135	151
销售、一般及管理费用	102	85	75	78	76	60
研发	35	34	51	30	36	44
营业费用	143	119	126	109	113	104
其他非经营性收入 (费用)	5	-1	0	-8	0	--
税前利润	29	61	-4	22	22	34
所得税费用	17	25	4	10	7	2
净利润	12	35	-8	12	14	31
净利润增长	-45%	-538%	-167%	-14%	-55%	-39%
稀释后流通股数	13.2	13.1	13.1	13.8	14.1	15.3
股份同比变动 (YoY)	3%	0%	-5%	-2%	-8%	-4%
每股收益 (摊薄)	0.91	2.73	-0.66	0.87	1.01	2.09
每股收益增长率	-49%	-514%	-176%	-14%	-52%	-36%
自由现金流	-9	50	27	48	55	52
每股自由现金流	--	--	--	--	--	--
毛利率	69.64%	69.93%	75.43%	75.93%	69.23%	70.89%
营业利润率	14%	32.27%	1.16%	17.64%	10.76%	22.06%
净利率	4.66%	11.07%	-4.67%	6.41%	7.17%	14.55%
自由现金流利润率	-3.5%	15.82%	15.78%	25.66%	28.2%	24.41%
EBITDA	56	114	5	36	25	50
EBITDA 利润率	21.78%	36.07%	2.92%	19.25%	12.82%	23.47%
EBITDA 中的折旧与摊销	20	12	3	3	4	3
EBIT	36	102	2	33	21	47
EBIT 利润率	14%	32.27%	1.16%	17.64%	10.76%	22.06%
有效税率	58.62%	40.98%	-100%	45.45%	31.81%	5.88%

Follow-Up Questions

Eagle Pharmaceuticals Inc 的关键财务报表是什么？



EGRX 的关键财务比率是什么？



Eagle Pharmaceuticals Inc 的收入按细分市场或地理位置如何划分？



Eagle Pharmaceuticals Inc 是否盈利？



Eagle Pharmaceuticals Inc 有负债吗？



Eagle Pharmaceuticals Inc 的流通股有多少？



关键数据

前收盘价

$0.85

开盘价

$1.5

当日区间

$0.5 - $1.5

52周范围

$0.1 - $3.87

交易量

100

平均成交量

4.1K

每股收益（TTM）

0.92

股息收益率

市值

$6.4M

什么是 EGRX？

Eagle Pharmaceuticals, Inc. is a biotechnology pharmaceutical company, which focuses on developing and commercializing injectable products primarily in the metabolic critical care and oncology areas in the United States. The company is headquartered in Woodcliff Lake, New Jersey and currently employs 134 full-time employees. The company went IPO on 2014-02-12. The firm is focused on developing medicines that result in improvements in patients' lives. The firm's commercialized products include vasopressin, PEMFEXY, RYANODEX, BENDEKA, BELRAPZO, TREAKISYM (Japan), and BYFAVO and BARHEMSYS through its wholly owned subsidiary Acacia Pharma Inc. Its oncology and central nervous system (CNS)/metabolic critical care pipeline includes product candidates with the potential to address underserved therapeutic areas across multiple disease states. The firm also has a research and development facility in Cambridge, Massachusetts. The firm is also focused on developing medicines with the potential to become part of the personalized medicine paradigm in cancer care. The firm has office space in Palm Beach Gardens, Florida and Indianapolis, Indiana.

功能特性

交易策略